Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.